• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用苯并噻唑片段分子探测蛋白激酶 DYRK1A 的 ATP 结合口袋。

Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.

机构信息

The Norwegian Structural Biology Centre, Department of Chemistry, UiT The Arctic University of Norway , N-9037 Tromsø, Norway.

Pharmasum Therapeutics AS , Smørblomstvn. 36, N-9102 Kvaløysletta, Norway.

出版信息

J Med Chem. 2016 Nov 10;59(21):9814-9824. doi: 10.1021/acs.jmedchem.6b01086. Epub 2016 Oct 21.

DOI:10.1021/acs.jmedchem.6b01086
PMID:27736065
Abstract

DYRK1A has emerged as a potential target for therapies of Alzheimer's disease using small molecules. On the basis of the observation of selective DYRK1A inhibition by firefly d-luciferin, we have explored static and dynamic structural properties of fragment sized variants of the benzothiazole scaffold with respect to DYRK1A using X-ray crystallography and NMR techniques. The compounds have excellent ligand efficiencies and show a remarkable diversity of binding modes in dynamic equilibrium. Binding geometries are determined in part by interactions often considered "weak", including "orthogonal multipolar" types represented by, for example, F-CO, sulfur-aromatic, and halogen-aromatic interactions, together with hydrogen bonds that are modulated by variation of electron withdrawing groups. These studies show how the benzothiazole scaffold is highly promising for the development of therapeutic DYRK1A inhibitors. In addition, the subtleties of the binding interactions, including dynamics, show how full structural studies are required to fully interpret the essential physical determinants of binding.

摘要

DYRK1A 已成为使用小分子治疗阿尔茨海默病的潜在靶点。基于对萤火虫荧光素选择性 DYRK1A 抑制的观察,我们使用 X 射线晶体学和 NMR 技术研究了苯并噻唑支架的片段大小变体相对于 DYRK1A 的静态和动态结构特性。这些化合物具有优异的配体效率,并在动态平衡中表现出显著的结合模式多样性。结合构象部分由通常被认为是“弱”的相互作用决定,包括“正交多极”类型,例如 F-CO、硫芳基和卤芳基相互作用,以及由电子受主基团变化调制的氢键。这些研究表明,苯并噻唑支架在开发治疗性 DYRK1A 抑制剂方面具有很高的潜力。此外,结合相互作用的细微差别,包括动态,表明如何进行充分的结构研究以充分解释结合的基本物理决定因素。

相似文献

1
Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.用苯并噻唑片段分子探测蛋白激酶 DYRK1A 的 ATP 结合口袋。
J Med Chem. 2016 Nov 10;59(21):9814-9824. doi: 10.1021/acs.jmedchem.6b01086. Epub 2016 Oct 21.
2
Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.通过基于整合分子对接的虚拟筛选和动力学模拟研究,发现新型潜在小分子骨架作为 DYRK1A 抑制剂。
Molecules. 2022 Feb 9;27(4):1159. doi: 10.3390/molecules27041159.
3
10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.10-碘-11H-吲哚并[3,2-c]喹啉-6-羧酸是双重特异性酪氨酸磷酸酶样激酶1A(DYRK1A)的选择性抑制剂。
J Med Chem. 2015 Apr 9;58(7):3131-43. doi: 10.1021/jm501994d. Epub 2015 Mar 23.
4
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.新型吡啶并[3,4-g]喹唑啉衍生物作为 CLK1 和 DYRK1A 的抑制剂:合成、生物评价及结合模式分析。
Eur J Med Chem. 2019 Mar 15;166:304-317. doi: 10.1016/j.ejmech.2019.01.052. Epub 2019 Jan 26.
5
[]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.[]-具有稠合卤代吲哚结构的潜在 DYRK1A 抑制剂。
Molecules. 2019 Nov 13;24(22):4090. doi: 10.3390/molecules24224090.
6
Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.新型双重特异性酪氨酸磷酸化调节激酶 1A(DYRK1A)抑制剂的支架。
J Med Chem. 2018 Sep 13;61(17):7560-7572. doi: 10.1021/acs.jmedchem.7b01847. Epub 2018 Aug 23.
7
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.吲哚-3-氰基化合物作为基于片段的药物设计的 DYRK1A 抑制剂。
Molecules. 2018 Jan 24;23(2):64. doi: 10.3390/molecules23020064.
8
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.通过计算和实验方法鉴定 DYRK1A 的小分子抑制剂。
Int J Mol Sci. 2020 Sep 17;21(18):6826. doi: 10.3390/ijms21186826.
9
Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.作为DYRK1A抑制剂的β-咔啉结构/活性关系的计算与实验评估
Bioorg Med Chem Lett. 2014 Oct 15;24(20):4854-60. doi: 10.1016/j.bmcl.2014.08.054. Epub 2014 Sep 2.
10
Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.基于分子动力学模拟对吡啶并[2,3-d]嘧啶作为DYRK1A抑制剂作用机制的见解
Proteins. 2016 Aug;84(8):1108-23. doi: 10.1002/prot.25056. Epub 2016 May 14.

引用本文的文献

1
Unlocking the Therapeutic Potential of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitors in Alzheimer's Diseases.揭示双特异性酪氨酸磷酸化调节激酶1A抑制剂在阿尔茨海默病中的治疗潜力
Mol Neurobiol. 2025 Mar 5. doi: 10.1007/s12035-025-04806-8.
2
Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions.唐氏综合征与DYRK1A基因过表达:关系及未来治疗方向
Front Mol Neurosci. 2024 Jul 24;17:1391564. doi: 10.3389/fnmol.2024.1391564. eCollection 2024.
3
Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.
靶向癌症治疗中的Mirk/Dyrk1B激酶抑制剂
Pharmaceutics. 2024 Apr 11;16(4):528. doi: 10.3390/pharmaceutics16040528.
4
Design, synthesis and preliminary biological evaluation of rivastigmine-INDY hybrids as multitarget ligands against Alzheimer's disease by targeting butyrylcholinesterase and DYRK1A/CLK1 kinases.通过靶向丁酰胆碱酯酶和双特异性酪氨酸磷酸化调节激酶1A/细胞周期蛋白依赖性激酶1激酶,设计、合成并初步生物学评价卡巴拉汀-INDY杂合物作为抗阿尔茨海默病的多靶点配体。
RSC Med Chem. 2024 Feb 20;15(3):963-980. doi: 10.1039/d3md00708a. eCollection 2024 Mar 20.
5
DYRK1a Inhibitor Mediated Rescue of Models of Alzheimer's Disease-Down Syndrome Phenotypes.DYRK1a抑制剂介导的阿尔茨海默病-唐氏综合征表型模型的拯救
Front Pharmacol. 2022 Jul 19;13:881385. doi: 10.3389/fphar.2022.881385. eCollection 2022.
6
Organomediated cleavage of benzoyl group enables an efficient synthesis of 1-(6-nitropyridin-2-yl)thiourea and its application for developing F-labeled PET tracers.有机介导的苯甲酰基裂解方法可高效合成 1-(6-硝基吡啶-2-基)硫脲,并用于开发 F 标记的正电子发射断层扫描(PET)示踪剂。
Bioorg Chem. 2022 Jul;124:105804. doi: 10.1016/j.bioorg.2022.105804. Epub 2022 Apr 12.
7
Identification of Pharmacophoric Fragments of DYRK1A Inhibitors Using Machine Learning Classification Models.使用机器学习分类模型鉴定 DYRK1A 抑制剂的药效团片段。
Molecules. 2022 Mar 8;27(6):1753. doi: 10.3390/molecules27061753.
8
Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.通过基于整合分子对接的虚拟筛选和动力学模拟研究,发现新型潜在小分子骨架作为 DYRK1A 抑制剂。
Molecules. 2022 Feb 9;27(4):1159. doi: 10.3390/molecules27041159.
9
Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome.新型双重特异性酪氨酸磷酸化调节激酶1A(DYRK1A)抑制剂可挽救唐氏综合征小鼠模型的学习和记忆缺陷。
Pharmaceuticals (Basel). 2021 Nov 17;14(11):1170. doi: 10.3390/ph14111170.
10
from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.从基因功能在发育和生理到唐氏综合征整个生命周期的剂量校正。
Genes (Basel). 2021 Nov 20;12(11):1833. doi: 10.3390/genes12111833.